Literature DB >> 31350587

The split scar sign as an indicator of sustained complete response after neoadjuvant therapy in rectal cancer.

Inês Santiago1,2, Maria Barata3, Nuno Figueiredo4, Oriol Parés5, Vanessa Henriques6, António Galzerano6, Carlos Carvalho7, Celso Matos3, Richard J Heald4.   

Abstract

OBJECTIVES: To measure the diagnostic performance of a new radiologic pattern on restaging magnetic resonance (MR) high-resolution T2-weighted imaging (T2-WI)-the split scar sign-for the identification of sustained complete response (SCR) after neoadjuvant therapy in rectal cancer.
METHODS: Institutional review board approval was obtained for this retrospective study and the informed consent requirement was waived. Fifty-eight consecutive patients with rectal cancer who underwent neoadjuvant therapy were enrolled. Two radiologists blindly and independently reviewed restaging pelvic MR imaging and recorded the presence/absence of the split scar sign (mrSSS). On a second round, they also assessed the relative proportion of intermediate signal intensity on T2-WI (mrT2) and of high signal intensity on high b-value diffusion-weighted imaging (mrDWI). Endoscopic response grading records were retrieved. Qui-square test was employed in search for associations between SCR, defined as pathologic complete response or long-term recurrence-free clinical follow-up, and mrSSS, mrT2, mrDWI and endoscopy. Interobserver agreement for imaging parameters was estimated using Cohen's kappa (k).
RESULTS: mrSSS was significantly associated with SCR, with specificity = 0.97/0.97, sensitivity = 0.52/0.64, PPV = 0.93/0.94, NPV = 0.73/0.78, and AuROC = 0.78/0.83, for observers 1/2, respectively. mrDWI was significantly associated with SCR for observer 2, with specificity = 0.76, sensitivity = 0.60, PPV = 0.65, NPV = 0.71, and AuROC = 0.69. mrT2 and endoscopy were not discriminative. Interobserver agreement was substantial for mrSSS (k = 0.69), moderate for mrDWI (k = 0.46), and poor for mrT2 (k = 0.17).
CONCLUSION: The split scar sign is a simple morphologic pattern visible on restaging T2-WI which, although not sensitive, is very specific for the identification of sustained complete responders after neoadjuvant therapy in rectal cancer. KEY POINTS: • The split scar sign is a morphologic pattern visible on high-resolution T2-weighted MR imaging in rectal cancer patients after neoadjuvant therapy. It therefore does not require any changes to standard protocol. • At first restaging pelvic MR imaging (mean: 9.1 weeks after the end of radiotherapy), the split scar sign identified patients who sustained a complete response with very high specificity (0.97) and positive predictive value (0.93-0.94). • The split scar sign has the potential to improve patient selection for "watch-and-wait" after neoadjuvant therapy in rectal cancer.

Entities:  

Keywords:  Magnetic resonance imaging; Neoadjuvant therapy; Rectal neoplasms; Watchful waiting

Mesh:

Year:  2019        PMID: 31350587     DOI: 10.1007/s00330-019-06348-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  Diffusion-weighted MRI to assess response to chemoradiotherapy in rectal cancer: main interpretation pitfalls and their use for teaching.

Authors:  Doenja M J Lambregts; Miriam M van Heeswijk; Andrea Delli Pizzi; Saskia G C van Elderen; Luisa Andrade; Nicky H G M Peters; Peter A M Kint; Margreet Osinga-de Jong; Shandra Bipat; Rik Ooms; Max J Lahaye; Monique Maas; Geerard L Beets; Frans C H Bakers; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

2.  Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Fraser M Smith; Homer Wiland; Adam Mace; Rish K Pai; Matthew F Kalady
Journal:  Dis Colon Rectum       Date:  2014-03       Impact factor: 4.585

3.  A Pattern-Based Approach Combining Tumor Morphology on MRI With Distinct Signal Patterns on Diffusion-Weighted Imaging to Assess Response of Rectal Tumors After Chemoradiotherapy.

Authors:  Doenja M J Lambregts; Andrea Delli Pizzi; Max J Lahaye; Joost J M van Griethuysen; Monique Maas; Geerard L Beets; Frans C H Bakers; Regina G H Beets-Tan
Journal:  Dis Colon Rectum       Date:  2018-03       Impact factor: 4.585

4.  Response assessment after (chemo)radiotherapy for rectal cancer: Why are we missing complete responses with MRI and endoscopy?

Authors:  Marit E van der Sande; Geerard L Beets; Britt Jp Hupkens; Stéphanie O Breukink; Jarno Melenhorst; Frans Ch Bakers; Doenja Mj Lambregts; Heike I Grabsch; Regina Gh Beets-Tan; Monique Maas
Journal:  Eur J Surg Oncol       Date:  2018-11-24       Impact factor: 4.424

5.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

Authors:  Maxime J M van der Valk; Denise E Hilling; Esther Bastiaannet; Elma Meershoek-Klein Kranenbarg; Geerard L Beets; Nuno L Figueiredo; Angelita Habr-Gama; Rodrigo O Perez; Andrew G Renehan; Cornelis J H van de Velde
Journal:  Lancet       Date:  2018-06-23       Impact factor: 79.321

6.  Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.

Authors:  Alexander K P Chan; Alfred Wong; Daryl Jenken; John Heine; Donald Buie; Douglas Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

7.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

8.  The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy.

Authors:  F M Smith; K H Chang; K Sheahan; J Hyland; P R O'Connell; D C Winter
Journal:  Br J Surg       Date:  2012-02-20       Impact factor: 6.939

9.  Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity.

Authors:  Paul Hatfield; Mohan Hingorani; Ganesh Radhakrishna; Rachel Cooper; Alan Melcher; Adrian Crellin; Michelle Kwok-Williams; David Sebag-Montefiore
Journal:  Radiother Oncol       Date:  2009-05-04       Impact factor: 6.280

10.  Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study.

Authors:  Calin Radu; Ake Berglund; Lars Påhlman; Bengt Glimelius
Journal:  Radiother Oncol       Date:  2008-02-21       Impact factor: 6.280

View more
  6 in total

Review 1.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

2.  MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology.

Authors:  Seong Ho Park; Seung Hyun Cho; Sang Hyun Choi; Jong Keon Jang; Min Ju Kim; Seung Ho Kim; Joon Seok Lim; Sung Kyoung Moon; Ji Hoon Park; Nieun Seo
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

3.  MRI Evaluation of Complete and Near-Complete Response after Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer.

Authors:  Anca-Raluca Popita; Cosmin Lisencu; Adriana Rusu; Cristian Popita; Calin Cainap; Alexandru Irimie; Liliana Resiga; Alina Munteanu; Zsolt Fekete; Radu Badea
Journal:  Diagnostics (Basel)       Date:  2022-04-07

4.  T2 relaxation time for the early prediction of treatment response to chemoradiation in locally advanced rectal cancer.

Authors:  Yuxi Ge; Yanlong Jia; Xiaohong Li; Weiqiang Dou; Zhong Chen; Gen Yan
Journal:  Insights Imaging       Date:  2022-07-07

5.  MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer.

Authors:  Andrea Delli Pizzi; Antonio Maria Chiarelli; Piero Chiacchiaretta; Martina d'Annibale; Pierpaolo Croce; Consuelo Rosa; Domenico Mastrodicasa; Stefano Trebeschi; Doenja Marina Johanna Lambregts; Daniele Caposiena; Francesco Lorenzo Serafini; Raffaella Basilico; Giulio Cocco; Pierluigi Di Sebastiano; Sebastiano Cinalli; Antonio Ferretti; Richard Geoffrey Wise; Domenico Genovesi; Regina G H Beets-Tan; Massimo Caulo
Journal:  Sci Rep       Date:  2021-03-08       Impact factor: 4.996

Review 6.  Re-staging and follow-up of rectal cancer patients with MR imaging when "Watch-and-Wait" is an option: a practical guide.

Authors:  Inês Santiago; Bernardete Rodrigues; Maria Barata; Nuno Figueiredo; Laura Fernandez; Antonio Galzerano; Oriol Parés; Celso Matos
Journal:  Insights Imaging       Date:  2021-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.